Abstract: Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 ?m. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Abstract: The present invention relates to a filtering device for NBC weapons, comprising a hermetically sealed box structure (10), provided with an opening for the inlet of air and/or gas to be filtered and an opening for the outlet of filtered air and/or gas, and within which one or more plates (11) are arranged to define the walls of a course for said air and/or gas from said inlet and said outlet, the sides of the plates (11) facing said course supporting a layer (12) of an adsorbing material.

Abstract: Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 ?m; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Abstract: The invention relates to vessels having high mechanical performances, whose structure comprises a plurality of superimposed layers, each being devoted to a peculiar function, said structure being composed by: 25-80% by weight of a fabric constituted by PBO fibres and/or fibres from polyester type liquid crystals and/or high molecular weight polyethylene fibres; 2.5-15% by weight of a polyimide film and/or a polyetheretherketone film; 10-40% by weight of a rubber solution based on a nitrilic rubber; 0-35% by weight of rubber blends having self-sealant aptitude. The invention also relates to a method for the production of said vessels and particular rubber solutions of said vessels.

Abstract: A lyophilized composition comprising (a) a conjugate comprising a N-alkyl methacrylamide-based copolymer and an anthracycline glycoside linked through a peptide spacer to the copolymer and (b) a cosolubilizing agent may optionally also contain (c) a filler. Also optionally, a targeting moiety may be linked to the copolymer of the conjugate via a peptide spacer. An injectable solution of the conjugate is obtained by reconstitution of the lyophilized composition.

Abstract: A stable lyophilized formulation of a fibroblast growth factor (FGF) comprises the FGF, a pharmaceutically acceptable bulking agent and either(a) an alkali metal salt of a carboxyalkyl cellulose, or(b) a polyoxyethylene sorbitan fatty acid ester and cysteine.